2008 Clinical Practice Guidelines - Canadian Diabetes Association

2008 CLINICAL PRACTICE GUIDELINES
S60
Med. 1998;338:861-866.
44. Meymeh RH, Wooltorton E. Diabetes drug pioglitazone
(Actos): risk of fracture. CMAJ. 2007;177:723-724.
45. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of
rosiglitazone, metformin, or glyburide monotherapy. N Engl J
Med. 2006;355:2427-2443.
46. Kahn SE, Zinman B, Lachin JM, et al; A Diabetes Outcome
Progression Trial (ADOPT) Study Group. Rosiglitazone-associated
fractures in type 2 diabetes: an analysis from A Diabetes
Outcome Progression Trial. Diabetes Care. 2008;31:845-851.
47. Miles JM, Leiter L, Hollander P, et al. Effect of orlistat in overweight
and obese patients with type 2 diabetes treated with
metformin. Diabetes Care. 2002;25:1123-1128.
48. Kelley DE, Bray GA, Pi-Sunyer FX, et al. Clinical efficacy of
orlistat therapy in overweight and obese patients with insulintreated
type 2 diabetes: A 1-year randomized controlled trial.
Diabetes Care. 2002;25:1033-1041.
49. Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in
the treatment of obese patients with type 2 diabetes. A 1-year
randomized double-blind study. Diabetes Care. 1998;21:1288-
1294.
50. Vettor R, Serra R, Fabris R, Pagano C, Federspil G. Effect of
sibutramine on weight management and metabolic control in
type 2 diabetes: a meta-analysis of clinical studies. Diabetes
Care. 2005;28:942-999.
51. Finer N, Bloom SR, Frost GS, et al. Sibutramine is effective for
weight loss and diabetic control in obesity with type 2 diabetes:
a randomised, double-blind, placebo-controlled study.
Diabetes Obes Metab. 2000;2:105-112.
52. UK Prospective Diabetes Study (UKPDS) Group. Effect of
intensive blood-glucose control with metformin on complications
in overweight patients with type 2 diabetes (UKPDS 34).
Lancet. 1998;352:854-865.
53. Avandia – Highlights of Prescribing Information. March 2008.
Research Triangle Park, NC: GlaxoSmithKline. Available at:
http://www.gsk.com/products/prescription_medicines/us
/medicines-ae.htm. Accessed September 1, 2008.
54. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of
myocardial infarction and death from cardiovascular causes.
N Engl J Med. 2007;356:2457-2471.
55. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular
events with rosiglitazone: a meta-analysis. JAMA. 2007;298:
1189-1195.
56. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary
prevention of macrovascular events in patients with type 2 diabetes
in the PROactive Study (PROspective pioglitAzone
Clinical Trial In macroVascular Events): a randomised controlled
trial. Lancet. 2005;366:1279-1289.
57. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone
Evaluated for Cardiovascular Outcomes – An interim analysis.
N Engl J Med. 2007;357:28-38.
58. The Action to Control Cardiovascular Risk in Diabetes Study
Group. Effects of intensive glucose lowering in type 2 diabetes.
N Engl J Med. 2008;358:2545-2559.
59. Yki-Järvinen H, Kauppila M, Kujansuu E, et al. Comparison of
insulin regimens in patients with non-insulin-dependent diabetes
mellitus. N Engl J Med. 1992;327:1426-1433.
60. Johnson JL, Wolf SL, Kabadi UM. Efficacy of insulin and sulfonylurea
combination therapy in type II diabetes. A metaanalysis
of the randomized placebo-controlled trials. Arch
Intern Med. 1996;156:259-264.
61. Yu JG, Krusynska MT, Mulford MI, et al. A comparison of
troglitazone and metformin on insulin requirements in euglycemic
intensively insulin-treated type 2 diabetic patients.
Diabetes. 1999;48:2414-2421.
62. Barnett AH, Dreyer M, Lange P, Serdarevic-Pehar M.An open,
randomized, parallel-group study to compare the efficacy and
safety profile of inhaled human insulin (Exubera) with metformin
as adjunctive therapy in patients with type 2 diabetes
poorly controlled on a sulfonylurea. Diabetes Care. 2006;29:
1282-1287.
63. American Diabetes Association. Implications of the United
Kingdom Prospective Diabetes Study. Diabetes Care. 1998;21:
2180-2184.
64. Abraira C, Colwell JA, Nuttall FQ, et al. Veterans Affairs
Cooperative Study on glycemic control and complications in
type II diabetes (VA CSDM). Results of the feasibility trial.
Diabetes Care. 1995;18:1113-1123.
65. Jennings AM, Wilson RM, Ward JD. Symptomatic hypoglycemia
in NIDDM patients treated with oral hypoglycemic
agents. Diabetes Care. 1989;12:203-208.
66. Anderson JH Jr, Brunelle RL, Keohane P, et al. Mealtime treatment
with insulin analog improves postprandial hyperglycemia
and hypoglycemia in patients with non-insulin-dependent diabetes
mellitus. Arch Intern Med. 1997;157:1249-1255.
67. Anderson JH Jr, Brunelle RL, Koivisto VA, et al. Improved
mealtime treatment of diabetes mellitus using an insulin analogue.
Clin Ther. 1997;19:62-72.
68. Yki-Järvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia
and better post-dinner glucose control with bedtime
insulin glargine compared with bedtime NPH insulin during
insulin combination therapy in type 2 diabetes. Diabetes Care.
2000;23:1130-1136.
69. Fritsche A, Schweitzer MA, Haring HU, et al. Glimepiride
combined with morning insulin glargine, bedtime neutral protamine
hagedorn insulin, or bedtime insulin glargine in
patients with type 2 diabetes. A randomized, controlled trial.
Ann Int Med. 2003;138:952-959.
70. Janka HU, Plewe G, Riddle MC, et al. Comparison of basal
insulin added to oral agents versus twice-daily premixed
insulin as initial insulin therapy for type 2 diabetes. Diabetes
Care. 2005;28:254-259.
71. Horvath K, Jeitler K, Berghold A, et al. A long-acting insulin
analogues versus NPH insulin (human isophane insulin) for
type 2 diabetes mellitus (Review). Cochrane Database Syst Rev.
2007;(2):CD005613.
72. Roach P,Yue L, Arora V. Improved postprandial glycemic control
during treatment with Humalog Mix25, a novel prota-